Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.
She has a BA in English from Penn State University. You can connect with Maggie on LinkedIn.
SDOH in Cancer Care Highlight Multifactorial Equity Issues
December 6th 2023A trio of speakers addressed the importance of social determinants of health (SDOH) in cancer care on day 1 of the 46th annual San Antonio Breast Cancer Symposium in the session, “Social Determinants of Health: Impact on Cancer Care.”
Read More
SABCS 2023 Sessions Touch on "Every Aspect of Breast Cancer"
December 4th 2023The 46th annual San Antonio Breast Cancer Symposium will take place December 5-9, with new and experienced attendees able to choose and learn from a schedule overflowing with the latest developments in breast cancer science and research.
Read More
New Data Update Myasthenia Gravis Outcomes for Patients in Australia
December 3rd 2023Patients living with myasthenia gravis in Australia were surveyed their demographic information, clinical features of the autoimmune disease, adverse effects from treatment, and quality of life. Outcomes were compared against 2011 data from Australia and 2019 data from the United States.
Read More
Gene Therapy Success in UK Likely Depends on Overcoming Education, Psychological Support Challenges
November 27th 2023Education, psychological support, and implementation guidance are the top unmet needs identified by investigators from the United Kingdom concerning gene therapy use for hemophilia.
Read More
In this interview with The American Journal of Managed Care®, Katie Queen, MD, addresses the complexity of obesity as a medical condition, pivoting to virtual care while ensuring that patients who lived in a rural location continued to receive adequate care, and the importance of integrating awareness of obesity and chronic disease prevention into local food culture.
Read More
Data on Delandistrogene Moxeparvovec Can Inform Future Gene Therapies
November 17th 2023The FDA approved delandistrogene moxeparvovec-rokl (Elevidys, Sarepta Therapeutics) in June to treat Duchenne muscular dystrophy in ambulatory pediatric patients aged 4 through 5 who have a confirmed DMD gene mutation.
Read More
Investigators Explore Potential Link Between the Gut Microbiome and Myasthenia Gravis Risk
November 14th 2023This new study sought to solidify a relationship between certain microbes in intestinal flora and the risk of developing myasthenia gravis, specifically those potentially reducing that risk.
Read More
Myasthenia Gravis Potential Result of Cancer Treatment
November 8th 2023When patients are undergoing treatment for cancer, clinicians should be aware of the potential to develop myasthenia gravis from immune checkpoint inhibitors (ICI), new research stresses, with ongoing surveillance and risk factor identification becoming necessary steps.
Read More
Wide Variation Seen in County-Level Breast Cancer Mortality Linked to SDOH
November 4th 2023Data from 2176 US counties link obesity and higher breast cancer mortality, while also showing varying degrees of association between mortality and access to healthy lifestyle options per social determinants of health (SDOH).
Read More
EOM Shows Awareness of Issues, but Provides No Resources, Says COA’s Nicolas Ferreyros
November 4th 2023The Enhancing Oncology Model is trying to address a number of the systemic challenges oncology faces without giving practices the tools and resources they need, said Nicolas Ferreyros, managing director of policy, advocacy, and communications, Community Oncology Alliance.
Read More
Despite Risk, Patients With SCD Hopeful About Gene Therapies
November 2nd 2023Sickle cell disease (SCD) has known complications that include organ damage and failure, rhabdomyolysis, glaucoma, splenic sequestration, and vaso-occlusive crises. At present, the only potential cure is a bone marrow transplant, but it can be difficult to find a donor and there is a high rejection risk.
Read More
Dr Afreen Idris Shariff: Cancer Care Can Transform Through e-Consults
November 2nd 2023Afreen Shariff, MD, MBBS, Duke Cancer Institute, discusses the challenges and benefits of electronic consults (e-consults) for patients with cancer currently undergoing treatment who have a comorbidity history or who develop an endocrine system disorder because of treatment.
Read More
Allina Health’s Mike Koroscik on Revolutionizing Early Cancer Detection Through Technology
October 26th 2023Through the integration of a population health reimbursement model in 2020, Allina Health Cancer Institute was able to implement expanded screening initiatives through the use of artificial intelligence and precision medicine, according to Mike Koroscik, MBA, MHA, vice president of oncology, Allina Health.
Read More
Exon-Skipping Therapy for DMD Linked to High Care Costs, Health Care Resource Utilization
October 25th 2023This comprehensive comparative analysis examined the economic and health care resource utilization implications of initiating glucocorticoid and exon-skipping therapy for Duchenne muscular dystrophy (DMD).
Read More
Innovating Community Oncology Care Delivery and Payment Reform: Insights From COA’s Ted Okon
October 25th 2023Ted Okon, MBA, executive director, Community Oncology Alliance, discusses early returns from the Enhancing Oncology Model and how community oncology practices are innovating in ways that can expand into other areas of medicine.
Read More
Dr Lalan Wilfong: Patients Deserve the Full Benefit of Everything We Can Provide
October 23rd 2023At the 2023 COA Payer Exchange Summit being held October 23-24 in Reston, Virginia, Lalan Wilfong, MD, US Oncology Network, emphasizes the importance of oncology care equity, ensuring continuity of care, and enhancing care coordination.
Read More
Case Report of Patient Death Following High-Dose Gene Therapy for DMD
October 19th 2023In this case study, a patient who had Duchenne muscular dystrophy (DMD) and received high-dose transgene therapy to upregulate cortical dystrophin subsequently developed acute respiratory distress syndrome and died.
Read More